Tower Research Capital (TRC)’s Lexaria Bioscience LEXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.6K Buy
1,778
+1,768
+17,680% +$13.4K ﹤0.01% 4599
2026
Q2
$85 Buy
+10
New +$108 ﹤0.01% 5140
2026
Q1
– Sell
-2
Closed -$22 – 5078
2025
Q4
$20 Sell
2
-239
-99% -$3.39K ﹤0.01% 5100
2025
Q3
$3.45K Buy
241
+110
+84% +$1.6K ﹤0.01% 4501
2025
Q2
$1.71K Buy
131
+44
+51% +$758 ﹤0.01% 4758
2025
Q1
$2.22K Sell
87
-52
-37% -$1.32K ﹤0.01% 4576
2024
Q4
$4.37K Buy
139
+49
+54% +$1.81K ﹤0.01% 4473
2024
Q3
$4.1K Sell
90
-135
-60% -$6.44K ﹤0.01% 4673
2024
Q2
$9.37K Buy
225
+45
+25% +$2.02K ﹤0.01% 4260
2024
Q1
$9.8K Sell
180
-207
-53% -$7.91K ﹤0.01% 3787
2023
Q4
$7.26K Sell
387
-168
-30% -$3.24K ﹤0.01% 4638
2023
Q3
$8.33K Sell
555
-175
-24% -$2.4K ﹤0.01% 4362
2023
Q2
$7.99K Buy
730
+457
+167% +$8.88K ﹤0.01% 4490
2023
Q1
$11K Sell
273
-62
-19% -$2.65K ﹤0.01% 4232
2022
Q4
$12K Buy
335
+93
+38% +$3.34K ﹤0.01% 3723
2022
Q3
$9K Buy
+242
New +$10.3K ﹤0.01% 4665
2022
Q2
– Sell
-204
Closed -$10K – 6330
2022
Q1
$10K Buy
204
+124
+155% +$7.02K ﹤0.01% 4318
2021
Q4
$5K Buy
+80
New +$6.83K ﹤0.01% 5163
2021
Q3
– Sell
-17
Closed -$2K – 5979
2021
Q2
$2K Buy
+17
New +$1.52K ﹤0.01% 5051

Other funds holding LEXX

Tower Research Capital (TRC)'s LEXX Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Lexaria Bioscience (LEXX) stake by 17,680% in Q3 2026, buying an estimated $13.4K and bringing the position to 1,778 shares worth $5.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4599.

Tower Research Capital (TRC) first reported a position in LEXX in Q2 2021 and has held it in 19 quarters since. The position peaked at $12K in Q4 2022. 15 funds tracked by Wall St. Rank hold LEXX as of Q3 2026.

  • Tower Research Capital (TRC) held 1,778 shares of Lexaria Bioscience worth $5.6K as of Q3 2026.
  • Tower Research Capital (TRC) bought 1,768 Lexaria Bioscience shares in Q3 2026, an estimated $13.4K.
  • Lexaria Bioscience made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4599 holding.
  • Tower Research Capital (TRC) first reported a position in Lexaria Bioscience in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Lexaria Bioscience position peaked at $12K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.